Beyond AirXAIR +3.44%27 FCF Margin % is -193.85% as of Dec. 2025. GuruFocus rates XAIR with a GF Score™ of 27/100 and a GF Value™ of $9.75 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Beyond Air ranks worse than 90.55% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Beyond Air's Free Cash Flow for the
three
months ended in Dec. 2025 was $-4.25 Mil. Beyond Air's Revenue for the
three
months ended in Dec. 2025 was $2.19 Mil. Therefore, Beyond Air's FCF Margin % for the quarter that ended in Dec. 2025 was -193.85%.
The historical rank and industry rank for Beyond Air's FCF Margin % or its related term are showing as below:
XAIR'
s FCF Margin % Range Over the Past 10 Years
Min: -5328.65 Med: -1190.31 Max: 16.64
Current: -319.63
During the past 11 years, the highest FCF Margin % of Beyond Air was 16.64%. The lowest was -5328.65%. And the median was -1190.31%.
XAIR's FCF Margin % is ranked worse than 90.55% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: -0.1
vs XAIR: -319.63
Beyond Air FCF Margin % Related Terms
Beyond Air FCF Margin % Historical Data
* Premium members only.
The historical data trend for Beyond Air's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Beyond Air's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beyond Air FCF Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Beyond Air's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Beyond Air's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beyond Air (XAIR) has a FCF Margin % of -193.85% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beyond Air and its competitors. According to the industry distribution chart, Beyond Air ranks #738 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 90.6%.
Is Beyond Air's FCF Margin % too high?
Beyond Air's current FCF Margin % is -193.85%. Based on the distribution chart, Beyond Air ranks #738 out of 815 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Beyond Air has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Beyond Air's FCF Margin % compare to LUDG and INBS?
According to the Medical Devices & Instruments industry distribution chart, Beyond Air ranks #738 out of 815 companies for FCF Margin %. This places Beyond Air in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Beyond Air and its competitors. Beyond Air's current FCF Margin % is -193.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beyond Air stock overvalued right now?
Based on GuruFocus' analysis, Beyond Air (XAIR) is currently considered Possible Value Trap. The stock's GF Value™ is $9.75, compared to a current price of $0.49 — trading 95% below its estimated fair value. The current FCF Margin % is -193.85%. Beyond Air's overall GF Score™ is 27/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Beyond Air (XAIR), the current FCF Margin % is -193.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beyond Air (XAIR) Overvalued in 2026?
Based on GuruFocus' analysis, Beyond Air stock appears to be undervalued.
The current stock price of $0.49 is trading 95% below its estimated GF Value™ of $9.75.
GuruFocus considers Beyond Air to be Possible Value Trap.
Key valuation signals for XAIR:
FCF Margin %: -193.85%
GF Value™: $9.75 vs. price of $0.49 (95% below fair value)
No single metric tells the full story. See the XAIR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.
27GF Score
Get the complete analysis for XAIR
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XAIR has been successfully added to your 
